About this Journal Submit a Manuscript Table of Contents
Advances in Virology
Volume 2012 (2012), Article ID 637208, 8 pages
http://dx.doi.org/10.1155/2012/637208
Review Article

Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development

Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3010, Australia

Received 11 January 2012; Revised 13 February 2012; Accepted 13 February 2012

Academic Editor: Christoph Boesecke

Copyright © 2012 Gamze Isitman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Iaccino, M. Schiavone, G. Fiume, I. Quinto, and G. Scala, “The aftermath of the Merck's HIV vaccine trial,” Retrovirology, vol. 5, article 56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Kim, S. Rerks-Ngarm, J. L. Excler, and N. L. Michael, “HIV vaccines: lessons learned and the way forward,” Current Opinion in HIV and AIDS, vol. 5, no. 5, pp. 428–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. N. A. Wilson and D. I. Watkins, “Is an HIV vaccine possible?” Brazilian Journal of Infectious Diseases, vol. 13, no. 4, pp. 304–310, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand,” New England Journal of Medicine, vol. 361, no. 23, pp. 2209–2220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. E. S. Svarovskaia, S. R. Cheslock, W. H. Zhang, W. S. Hu, and V. K. Pathak, “Retroviral mutation rates and reverse transcriptase fidelity,” Frontiers in Bioscience, vol. 8, pp. d117–d134, 2003. View at Scopus
  6. A. Onafuwa-Nuga and A. Telesnitsky, “The remarkable frequency of human immunodeficiency virus type 1 genetic recombination,” Microbiology and Molecular Biology Reviews, vol. 73, no. 3, pp. 451–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. D. Richman, T. Wrin, S. J. Little, and C. J. Petropoulos, “Rapid evolution of the neutralizing antibody response to HIV type 1 infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4144–4149, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. E. Phillips, S. Rowland-Jones, D. F. Nixon et al., “Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition,” Nature, vol. 354, no. 6353, pp. 453–459, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. A. W. Chung, G. Isitman, M. Navis et al., “Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 18, pp. 7505–7510, 2011. View at Publisher · View at Google Scholar
  10. C. S. Fernandez, I. Stratov, R. De Rose et al., “Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost,” Journal of Virology, vol. 79, no. 9, pp. 5721–5731, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. Leslie, K. J. Pfafferott, P. Chetty et al., “HIV evolution: CTL escape mutation and reversion after transmission,” Nature Medicine, vol. 10, no. 3, pp. 282–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. A. Goepfert, W. Lumm, P. Farmer et al., “Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients,” Journal of Experimental Medicine, vol. 205, no. 5, pp. 1009–1017, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. M. Allen and M. Altfeld, “Crippling HIV one mutation at a time,” Journal of Experimental Medicine, vol. 205, no. 5, pp. 1003–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. J. Kent, C. S. Fernandez, C. J. Dale, and M. P. Davenport, “Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity,” Trends in Microbiology, vol. 13, no. 6, pp. 243–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Leslie, K. J. Pfafferott, P. Chetty et al., “HIV evolution: CTL escape mutation and reversion after transmission,” Nature Medicine, vol. 10, no. 3, pp. 282–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Herbeck, M. Rolland, W. Deng, A. Collier, and J. Mullins, in AIDS Vaccine, A. L. Ross, Ed., vol. 6, Paris, France, 2009.
  17. N. Goonetilleke, M. K. P. Liu, J. F. Salazar-Gonzalez et al., “The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection,” Journal of Experimental Medicine, vol. 206, no. 6, pp. 1253–1272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Kearney, F. Maldarelli, W. Shao et al., “Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals,” Journal of Virology, vol. 83, no. 6, pp. 2715–2727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Li, A. D. Gladden, M. Altfeld et al., “Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution,” Journal of Virology, vol. 81, no. 1, pp. 193–201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. L. Boutwell, C. F. Rowley, and M. Essex, “Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein,” Journal of Virology, vol. 83, no. 6, pp. 2460–2468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Brockman, A. Schneidewind, M. Lahaie et al., “Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A,” Journal of Virology, vol. 81, no. 22, pp. 12608–12618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Schneidewind, M. A. Brockman, J. Sidney et al., “Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid,” Journal of Virology, vol. 82, no. 11, pp. 5594–5605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Crawford, W. Lumm, A. Leslie et al., “Evolution of HLA-B 5703 hiv-1 escape mutations in HLA-B 5703-positive individuals and their transmission recipients,” Journal of Experimental Medicine, vol. 206, no. 4, pp. 909–921, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. M. Troyer, J. McNevin, Y. Liu et al., “Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response,” PLoS Pathogens, vol. 5, no. 4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Peut and S. J. Kent, “Substantial envelope-specific CD8 T-cell immunity fails to control siv disease,” Virology, vol. 384, no. 1, pp. 21–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Peut and S. J. Kent, “Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen,” Journal of Virology, vol. 81, no. 23, pp. 13125–13134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. H. Barouch, J. Kunstman, M. J. Kuroda et al., “Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lynphocytes,” Nature, vol. 415, no. 6869, pp. 335–339, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. C. L. Boutwell, A. Schneidewind, Z. Brumme et al., “P09-19 LB. CTL escape mutations in gag epitopes restricted by protective HLA class I alleles cause substantial reductions in viral replication capacity,” Retrovirology, vol. 6, no. 3, article 1742, p. P399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Streeck, J. S. Jolin, Y. Qi et al., “Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells,” Journal of Virology, vol. 83, no. 15, pp. 7641–7648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Miura, M. A. Brockman, C. J. Brumme et al., “Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes,” Journal of Virology, vol. 82, no. 17, pp. 8422–8430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Miura, C. J. Brumme, M. A. Brockman et al., “HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers,” Journal of Virology, vol. 83, no. 7, pp. 3407–3412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Miura, M. A. Brockman, A. Schneidewind et al., “HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphotye recognition,” Journal of Virology, vol. 83, no. 6, pp. 2743–2755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Miura, M. A. Brockman, Z. L. Brumme et al., “HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1,” Journal of Virology, vol. 83, no. 1, pp. 140–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. R. Chopera, Z. Woodman, K. Mlisana et al., “Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage,” PLoS Pathogens, vol. 4, no. 3, Article ID e1000033, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C. L. Boutwell, M. M. Rolland, J. T. Herbeck, J. I. Mullins, and T. M. Allen, “Viral evolution and escape during acute HIV-1 infection,” The Journal of Infectious Diseases, vol. 202, supplement, pp. S309–S314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Rolland, S. Tovanabutra, A. C. Decamp et al., “Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial,” Nature Medicine, vol. 17, no. 3, pp. 366–372, 2011. View at Publisher · View at Google Scholar
  37. N. L. Haigwood and L. Stamatatos, “Role of neutralizing antibodies in HIV infection,” AIDS, vol. 17, supplement, pp. S67–S71, 2003. View at Scopus
  38. P. W. Parren, J. P. Moore, D. R. Burton, and Q. J. Sattentau, “The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity,” AIDS, vol. 13, supplement, pp. S137–162, 1999. View at Scopus
  39. T. W. Baba, V. Liska, R. Hofmann-Lehmann et al., “Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection,” Nature Medicine, vol. 6, no. 2, pp. 200–206, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. J. R. Mascola, G. Stiegler, T. C. Vancott et al., “Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies,” Nature Medicine, vol. 6, no. 2, pp. 207–210, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. J. R. Mascola, M. G. Lewis, G. Stiegler et al., “Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies,” Journal of Virology, vol. 73, no. 5, pp. 4009–4018, 1999. View at Scopus
  42. R. S. Veazey, R. J. Shattock, M. Pope et al., “Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120,” Nature Medicine, vol. 9, no. 3, pp. 343–346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. N. L. Haigwood, D. C. Montefiori, W. F. Sutton et al., “Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies,” Journal of Virology, vol. 78, no. 11, pp. 5983–5995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. P. W. H. I. Parren, P. A. Marx, A. J. Hessell et al., “Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro,” Journal of Virology, vol. 75, no. 17, pp. 8340–8347, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Poignard, R. Sabbe, G. R. Picchio et al., “Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo,” Immunity, vol. 10, no. 4, pp. 431–438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. M. C. Gauduin, P. W. H. I. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup, “Passive immunization with a human monoclonal antibody protects hu-PBL- SCID mice against challenge by primary isolates of HIV-1,” Nature Medicine, vol. 3, no. 12, pp. 1389–1393, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Moog, H. J. A. Fleury, I. Pellegrin, A. Kirn, and A. M. Aubertin, “Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals,” Journal of Virology, vol. 71, no. 5, pp. 3734–3741, 1997. View at Scopus
  48. A. Pinter, W. J. Honnen, S. C. Kayman, O. Trochev, and Z. Wu, “Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120,” Vaccine, vol. 16, no. 19, pp. 1803–1811, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Cao, L. Qin, L. Zhang, J. Safrit, and D. D. Ho, “Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection,” New England Journal of Medicine, vol. 332, no. 4, pp. 201–208, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Carotenuto, D. Looij, L. Keldermans, F. De Wolf, and J. Goudsmit, “Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection,” AIDS, vol. 12, no. 13, pp. 1591–1600, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. D. C. Montefiori, G. Pantaleo, L. M. Fink et al., “Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors,” Journal of Infectious Diseases, vol. 173, no. 1, pp. 60–67, 1996. View at Scopus
  52. A. K. Pilgrim, G. Pantaleo, O. J. Cohen et al., “Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term—nonprogressive infection,” Journal of Infectious Diseases, vol. 176, no. 4, pp. 924–932, 1997. View at Scopus
  53. Y. J. Zhang, C. Fracasso, J. R. Fiore et al., “Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1- infected long-term nonprogressors,” Journal of Infectious Diseases, vol. 176, no. 5, pp. 1180–1187, 1997. View at Scopus
  54. X. Wei, J. M. Decker, S. Wang et al., “Antibody neutralization and escape by HIV-1,” Nature, vol. 422, no. 6929, pp. 307–312, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Trkola, H. Kuster, P. Rusert et al., “Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies,” Nature Medicine, vol. 11, no. 6, pp. 615–622, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. N. L. Haigwood, A. Watson, W. F. Sutton et al., “Passive immune globulin therapy in the SIV/macaque model: early interventisn can alter disease profile,” Immunology Letters, vol. 51, no. 1-2, pp. 107–114, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Nishimura, T. Igarashi, N. L. Haigwood et al., “Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15131–15136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Yamamoto, M. Kawada, A. Takeda, H. Igarashi, and T. Matano, “Post-infection immunodeficiency virus control by neutralizing antibodies,” PloS One, vol. 2, no. 6, p. e540, 2007. View at Scopus
  59. A. J. Hessell, P. Poignard, M. Hunter et al., “Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques,” Nature Medicine, vol. 15, no. 8, pp. 951–954, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. A. J. Hessell, E. G. Rakasz, D. M. Tehrani et al., “Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L,” Journal of Virology, vol. 84, no. 3, pp. 1302–1313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Goonetilleke, M. K. P. Liu, J. F. Salazar-Gonzalez et al., “The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection,” Journal of Experimental Medicine, vol. 206, no. 6, pp. 1253–1272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Jain, A. J. Patrick, and K. L. Rosenthal, “Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen,” Vaccine, vol. 28, no. 43, pp. 7070–7080, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. O. Alsmadi, R. Herz, E. Murphy, A. Pinter, and S. A. Tilley, “A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection,” Journal of Virology, vol. 71, no. 2, pp. 925–933, 1997. View at Scopus
  64. R. A. Koup, J. E. Robinson, Q. V. Nguyen et al., “Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1,” AIDS, vol. 5, no. 11, pp. 1309–1314, 1991. View at Scopus
  65. O. Alsmadi and S. A. Tilley, “Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities,” Journal of Virology, vol. 72, no. 1, pp. 286–293, 1998. View at Scopus
  66. K. Broliden, A. Von Gegerfelt, C. Persson et al., “Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity,” AIDS Research and Human Retroviruses, vol. 12, no. 18, pp. 1699–1702, 1996. View at Scopus
  67. D. S. Tyler, S. D. Stanley, S. Zolla-Pazner et al., “Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies,” Journal of Immunology, vol. 145, no. 10, pp. 3276–3282, 1990. View at Scopus
  68. U. H. M. Ziegner, I. Frank, A. Bernatowicz, S. E. Starr, and H. J. Streckert, “Antibody-dependent cellular cytotoxicity (ADCC) is directed against immunodominant epitopes of the envelope proteins of human immunodeficiency virus 1 (HIV-1),” Viral Immunology, vol. 5, no. 4, pp. 273–281, 1992. View at Scopus
  69. M. Duval, M. R. Posner, and L. A. Cavacini, “A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils,” Journal of Virology, vol. 82, no. 9, pp. 4671–4674, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. R. H. Florese, T. Demberg, P. Xiao et al., “Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines,” Journal of Immunology, vol. 182, no. 6, pp. 3718–3727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Yamada and A. Iwamoto, “Expression of a novel Nef epitope on the surface of HIV type 1-infected cells,” AIDS Research and Human Retroviruses, vol. 15, no. 11, pp. 1001–1009, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Yamada, N. Watanabe, T. Nakamura, and A. Iwamoto, “Antibody-dependent cellular cytotoxicity via humoral immune epitope of nef protein expressed on cell surface,” Journal of Immunology, vol. 172, no. 4, pp. 2401–2406, 2004. View at Scopus
  73. A. J. Hessell, L. Hangartner, M. Hunter et al., “Fc receptor but not complement binding is important in antibody protection against HIV,” Nature, vol. 449, no. 7158, pp. 101–104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. V. R. Gómez-Román, L. J. Patterson, D. Venzon et al., “Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251,” Journal of Immunology, vol. 174, no. 4, pp. 2185–2189, 2005.
  75. G. Isitman, A. W. Chung, M. Navis, S. J. Kent, and I. Stratov, “Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection,” Virology, vol. 412, no. 1, pp. 110–116, 2011. View at Publisher · View at Google Scholar
  76. I. Stratov, A. Chung, and S. J. Kent, “Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects,” Journal of Virology, vol. 82, no. 11, pp. 5450–5459, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Isitman, A. Chung, M. Navis, I. Stratov, and S. Kent, “ADCC immunity to HIV-1 Pol,” in Proceedings of the Annual Conference of the Australasian Society for HIV Medicine (ASHM '11), Canberra, Australia, 2011.
  78. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand,” New England Journal of Medicine, vol. 361, no. 23, pp. 2209–2220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. B. Haynes, AIDS Vaccine, Bangkok, Thailand, 2011.
  80. V. Peut and S. J. Kent, “Substantial envelope-specific CD8 T-cell immunity fails to control siv disease,” Virology, vol. 384, no. 1, pp. 21–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. A. D. Kelleher, C. Long, E. C. Holmes et al., “Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses,” Journal of Experimental Medicine, vol. 193, no. 3, pp. 375–385, 2001. View at Publisher · View at Google Scholar · View at Scopus
  82. L. L. Lanier, “Up on the tightrope: natural killer cell activation and inhibition,” Nature Immunology, vol. 9, no. 5, pp. 495–502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Alter, M. P. Martin, N. Teigen et al., “Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes,” Journal of Experimental Medicine, vol. 204, no. 12, pp. 3027–3036, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. M. P. Martin, X. Gao, J. H. Lee et al., “Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS,” Nature Genetics, vol. 31, no. 4, pp. 429–434, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Alter, D. Heckerman, A. Schneidewind et al., “HIV-1 adaptation to NK-cell-mediated immune pressure,” Nature, vol. 476, no. 7358, pp. 96–101, 2011. View at Publisher · View at Google Scholar